47
Views
0
CrossRef citations to date
0
Altmetric
Corrigendum

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]

Page 613 | Published online: 27 Mar 2018
This article refers to:
Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study

Restelli U, Ceresoli GL, Croce D et al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Management and Research. 2017;9:789–800.

On page 796, above the Disclosure section, the Acknowledgment section is missing. The missing text is:

Acknowledgments

The authors thank Ray Hill, an independent medical writer, who provided English-language editing and journal styling prior to submission on behalf of Health Publishing & Services Srl. Editorial support was funded through an unconditional contribution by Bayer SpA.